Sunnybrook Research Institute (Glypican-3)

Innovation Type:
Diagnostics
Cancer Type:
Liver
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Glypican-3: a novel marker for the early diagnosis of hepatocellular carcinoma

Related news

There are currently no news items related to this portfolio company.

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.